ArticleInternational journal of clinical oncology2025
Elevated proportion of eosinophils predicts immune-related adverse events and improved survival in patients with gastric cancer treated with nivolumab.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tislelizumab combined with gemcitabine plus cisplatin for muscle-invasive upper tract urothelial carcinoma: A retrospective single-center cohort analysis.The Journal of international medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have improved treatment outcomes for gastric cancer. However, immune-related adverse events (irAEs) pose a major challenge. This study aimed to identify predictive factors for irAE occurrence in patients with advanced or recurrent gastric cancer treated with nivolumab.
methodsWe retrospectively analyzed information of 115 patients with advanced or recurrent gastric cancer treated with nivolumab monotherapy or in combination with chemotherapy. Patient characteristics and laboratory data, including complete blood counts, and clinical outcomes were analyzed. Optimal cutoffs for potential predictive factors were determined using ROC curve analysis.
resultsirAEs developed in 21 patients, with a median onset time of 124 days after treatment initiation. Patients with an eosinophil proportion ≥ 4% showed higher irAE rates compared to those with < 4%. Multivariate analysis identified eosinophil proportion ≥ 4% (odds ratio 5.0) and neutrophil-to-lymphocyte ratio < 1.9 (odds ratio 4.6) as independent predictors of irAE occurrence. Patients with an elevated eosinophil proportion had higher levels throughout the treatment than those without irAEs at baseline, two months, and three months after treatment initiation. Patients with eosinophil proportions ≥ 4% demonstrated better overall survival and a tendency toward improved progression-free survival.
conclusionElevated eosinophil proportion before ICI treatment was a predictor of irAE occurrence and was associated with improved survival in patients with advanced or recurrent gastric cancer. This readily available clinical parameter may help identify patients more likely to benefit from ICI therapy, while enabling closer monitoring of potential irAEs.
Indexed as
Identifiers
41160300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.